Neostigmine Methylsulfate Injection Ready-to-Fill Syringes Launched – APhA submits compounding comments to FDA. – (866) 348-2889.
The Neostigmine Methylsulfate Injection, USP in 3 mg per 3 ml, has just been released in ready-to-administer prefilled syringes through Fresenius Kabi, which specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The drug is used to reverse the effects of non-depolarizing neuromuscular blocking agents (NMBA) after surgery.
The first manufacturer-prepared, ready-to-administer prefilled syringe on the market, the Fresenius Kabi Simplist Neostigmine Injection, USP has also been sold in 0.5 mg per 1 ml and 1 mg per 1 ml vial presentations since 2015.